SKK
CKPT

Shepherd Kaplan Krochuk’s Checkpoint Therapeutics CKPT Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$30K – 165
2019
Q2 		$30K Sell
1,000
-4,000
-80% -$157K 0.02% 161
2019
Q1 		$143K Hold
5,000
– – 0.09% 159
2018
Q4 		$91K Buy
5,000
+1,000
+25% +$23.8K 0.06% 164
2018
Q3 		$143K Buy
+4,000
New +$140K 0.07% 191

Other funds holding CKPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Shepherd Kaplan Krochuk's CKPT Position: Q3 2019 in Review

Shepherd Kaplan Krochuk sold out of Checkpoint Therapeutics (CKPT) in Q3 2019, closing a stake of 1,000 shares — an estimated $30K sold.

Shepherd Kaplan Krochuk first reported a position in CKPT in Q3 2018 and held it in 4 quarters. The position peaked at $143K in Q1 2019. 37 funds tracked by Wall St. Rank hold CKPT as of Q3 2019.

  • Shepherd Kaplan Krochuk reported no remaining Checkpoint Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 1,000 Checkpoint Therapeutics shares in Q3 2019, an estimated $30K.
  • Shepherd Kaplan Krochuk first reported a position in Checkpoint Therapeutics in Q3 2018 and held it in 4 quarters.
  • Shepherd Kaplan Krochuk's Checkpoint Therapeutics position peaked at $143K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2019.

Based on Shepherd Kaplan Krochuk's 13F filing for Q3 2019, filed 12 Nov 2019.